Translational Research Program to Advance Clinical Outcomes in Acute Myeloid Leukaemia

推进急性髓系白血病临床结果的转化研究计划

• 批准号: nhmrc : 1141460
• 负责人: A/Pr Andrew Wei
• 金额: $ 27.89万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: Practitioner Fellowships
• 财政年份: 2018
• 资助国家: 澳大利亚
• 起止时间: 2018-01-01 至 2022-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/translational-research-program-myeloid-leukaemia/1319470
• 关键词: Translational; Research; Program; Advance; Clinical

Five-year survival in acute myeloid leukaemia (AML) is only 27%, placing it amongst the worst-ranked cancers for clinical outcome. Improved patient outcomes will be achieved through implementation of a Translational Research Program to support novel agent drug testing, early-phase and randomised clinical trials and a national clinical registry to audit outcomes. New insights into leukaemic stem cell function and mechanisms of drug resistance will inform the design of future clinical trials.

急性髓性白血病（AML）的五年生存率仅为27%，是临床结局最差的癌症之一。将通过实施转化研究计划来改善患者结局，以支持新药试验、早期和随机临床试验以及国家临床登记处来审计结局。对白血病干细胞功能和耐药机制的新见解将为未来临床试验的设计提供信息。